What Pfizer brands will Cipla now sell in India?

Cipla will market and sell Pfizer's cough syrups Corex Dx and Corex LS, the NSAID Dolonex, the PPI Neksium, and the oral antibiotic Dalacin C in India.

Is this the first partnership between Cipla and Pfizer in India?

Yes, this exclusive agreement marks the first-ever partnership between Cipla and Pfizer in the Indian market.

Who will manufacture the medicines Cipla is distributing for Pfizer?

Pfizer will continue to manufacture, source, and supply these medicines to Cipla for distribution within India.

Home / Business and Economy / Cipla Partners Pfizer for Wider Drug Access

Cipla Partners Pfizer for Wider Drug Access

19 Dec

•

Summary

Cipla gains exclusive rights to market four Pfizer brands in India.
Pfizer will continue manufacturing and supplying the specified medicines.
This marks the first collaboration between Pfizer and Cipla in India.

Cipla Partners Pfizer for Wider Drug Access

Cipla Ltd. has secured an exclusive agreement with Pfizer India, positioning it to market, distribute, and sell four key Pfizer brands throughout India. This strategic alliance, announced recently, empowers Cipla with sole rights for prominent medications.

Under this pact, Cipla will manage the distribution of the cough syrups Corex Dx and Corex LS, the anti-inflammatory drug Dolonex, the proton pump inhibitor Neksium, and the antibiotic Dalacin C. Pfizer will maintain its role in manufacturing and supplying these essential medicines to Cipla for the Indian market, ensuring continuity and quality.

This collaboration signifies a significant step for both companies, marking their first partnership in India. The union is expected to enhance patient access to Pfizer's trusted portfolio by combining it with Cipla's deep-rooted distribution network and market expertise, addressing the healthcare needs of millions across the nation.